Geertjan van Tienhoven
Overview
Explore the profile of Geertjan van Tienhoven including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
121
Citations
4384
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Valverde C, Bakker A, Kok H, Kolff M, van Tienhoven G, Kostoulas P, et al.
Int J Radiat Oncol Biol Phys
. 2025 Mar;
PMID: 40057286
Purpose: Mild hyperthermia (HT) (39-43°C) combined with re-irradiation is considered for patients with locoregional recurrent (LRR) breast cancer. Studies analyzing dichotomized HT thermal dose (TD) parameters suggest that higher TD...
2.
Wismans L, Hendriks T, Suurmeijer J, Nuyttens J, Bruynzeel A, Intven M, et al.
Br J Surg
. 2025 Feb;
112(2).
PMID: 39891429
Background: Postoperative pancreatic fistula is the main driver of morbidity and mortality after pancreatoduodenectomy. In high-risk patients, the rate of postoperative pancreatic fistula approaches 50%, whereas it is below 5%...
3.
Veldman-Landegent J, van Kesteren Z, Parkes M, Stevens M, van den Aardweg J, Dieleman E, et al.
Adv Radiat Oncol
. 2024 Dec;
10(2):101679.
PMID: 39703719
Purpose: Accurate radiation therapy (RT) for lung cancer is challenging because of the respiratory motion of the tumor and surrounding organs at risk. Recently, non-invasive mechanical ventilation (NIMV) has been...
4.
Kaidar-Person O, Boersma L, De Brouwer P, Weltens C, Kirkove C, Peignaux-Casasnovas K, et al.
Radiother Oncol
. 2024 Sep;
201:110563.
PMID: 39341505
Material/methods: Data with a median follow-up of 15.7 years were extracted from the trial's case report forms. Kaplan-Meier curves of disease-free and OS and cumulative incidence curves of breast cancer...
5.
Suurmeijer J, Wismans L, Hendriks T, Bruynzeel A, Nuyttens J, Intven M, et al.
BMJ Open
. 2024 Sep;
14(9):e087193.
PMID: 39317507
Introduction: Postoperative pancreatic fistula (POPF) occurs in 25% of patients undergoing a high-risk pancreatoduodenectomy (PD) and is a driving cause of major morbidity, mortality, prolonged hospital stay and increased costs...
6.
Wismans L, Suurmeijer J, van Dongen J, Bonsing B, van Santvoort H, Wilmink J, et al.
Surgery
. 2024 Mar;
175(6):1580-1586.
PMID: 38448277
Background: Postoperative pancreatic fistula remains the leading cause of significant morbidity after pancreatoduodenectomy for pancreatic ductal adenocarcinoma. Preoperative chemoradiotherapy has been described to reduce the risk of postoperative pancreatic fistula,...
7.
Stoop T, Theijse R, Seelen L, Groot Koerkamp B, van Eijck C, Wolfgang C, et al.
Nat Rev Gastroenterol Hepatol
. 2023 Nov;
21(2):101-124.
PMID: 38036745
Surgical resection combined with systemic chemotherapy is the cornerstone of treatment for patients with localized pancreatic cancer. Upfront surgery is considered suboptimal in cases with extensive vascular involvement, which can...
8.
van Eijck C, Mustafa D, Vadgama D, de Miranda N, Groot Koerkamp B, van Tienhoven G, et al.
Gut
. 2023 Sep;
73(2):311-324.
PMID: 37709493
Background: This study investigates sex disparities in clinical outcomes and tumour immune profiles in patients with pancreatic ductal adenocarcinoma (PDAC) who underwent upfront resection or resection preceded by gemcitabine-based neoadjuvant...
9.
Valverde C, Ebrahimi G, Sprangers M, Pateras K, Bruynzeel A, Jacobs M, et al.
Int J Radiat Oncol Biol Phys
. 2023 Aug;
118(2):352-361.
PMID: 37647972
Purpose: Clinical evidence is limited regarding palliative radiation therapy for relieving pancreatic cancer-related pain. We prospectively investigated pain response after short-course palliative radiation therapy in patients with moderate-to-severe pancreatic cancer-related...
10.
Doppenberg D, van Dam J, Han Y, Bonsing B, Busch O, Festen S, et al.
Br J Surg
. 2023 Jul;
110(10):1374-1380.
PMID: 37440421
Background: Guidelines suggest that the serum carbohydrate antigen (CA19-9) level should be used when deciding on neoadjuvant treatment in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma (hereafter referred...